Histology
Basal Cell Carcinoma
CI-CAN-00000479Explore in graph →
57 active trials4 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000479Explore in graph →
Clinical trials
361 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (25)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04669808 | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma | completed | Phase 2 | 32 | SirnaomicsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04552990 | Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma | completed | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT00833417 |
| A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma |
| completed |
| Phase 2 |
| 104 |
| Genentech, Inc.INDUSTRY |
| 6 |
| May 11, 2026 |
| clinicaltrials |
| NCT00959647 | A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | completed | Phase 2 | 19 | Genentech, Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06608238 | Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma. | completed | Phase 2 | 90 | SkinJect, Inc.INDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT02667574 | Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)(VISMONEO) | completed | Phase 2 | 55 | University Hospital, LilleOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03534947 | A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma(SONIB) | completed | Phase 2 | 16 | Melanoma Institute AustraliaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05188729 | Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma | completed | Phase 2 | 92 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT03132636 | PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy | completed | Phase 2 | 138 | Regeneron PharmaceuticalsINDUSTRY | 10 | Apr 8, 2025 | clinicaltrials |
| NCT00604890 | Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma | completed | Phase 1 / Phase 2 | 186 | BPGbioINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04470726 | Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype(NMSC) | completed | Phase 1 / Phase 2 | 26 | AiViva BioPharma, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05713760 | Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults | completed | Phase 2 | 5 | Austin Institute for Clinical ResearchNETWORK | 1 | Jul 19, 2024 | clinicaltrials |
| NCT04416516 | Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor | completed | Phase 2 | 21 | Ascend Biopharmaceuticals LtdINDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03541252 | Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study | completed | Phase 1 / Phase 2 | 20 | Merete HaedersdalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03035188 | Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma(NICCI) | completed | Phase 2 | 40 | SRH Wald-Klinikum Gera GmbHOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03180528 | Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer | completed | Phase 2 | 30 | Kavita SarinOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT01835626 | Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma | completed | Phase 2 | 24 | Sue YomOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03714529 | A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma | completed | Phase 2 | 10 | Herlev and Gentofte HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02354261 | Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) | completed | Phase 2 | 38 | HedgePath Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01327053 | A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma(BOLT) | completed | Phase 2 | 230 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 28, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT01700049 | Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02690948 | Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer | completed | Phase 1 / Phase 2 | 16 | Anne ChangOTHER | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02828111 | Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas(BCC) | completed | Phase 2 | 36 | PellePharm, Inc.INDUSTRY | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01108094 | Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas | completed | Phase 2 | 29 | Stanford UniversityOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03569345 | Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate | completed | Phase 1 / Phase 2 | 20 | Merete HaedersdalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT01791894 | Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma(ATO) | completed | Phase 1 / Phase 2 | 5 | Stanford UniversityOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT02550678 | A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma(ASN-002-001) | completed | Phase 1 / Phase 2 | 16 | Ascend Biopharmaceuticals LtdINDUSTRY | 1 | Jun 6, 2018 | clinicaltrials |
| NCT02007317 | Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study | completed | Phase 2 | 30 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01815840 | A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas | completed | Phase 2 | 229 | Hoffmann-La RocheINDUSTRY | 10 | Sep 28, 2017 | clinicaltrials |
| NCT02029352 | Topical Green Tea Ointment in Treatment of Superficial Skin Cancer | completed | Phase 2 / Phase 3 | 42 | Maastricht University Medical CenterOTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT01325688 | PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities | completed | Phase 2 | 75 | PeplinINDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00432185 | To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC | completed | Phase 2 | 117 | PeplinINDUSTRY | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00089180 | T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01350115 | Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | completed | Phase 2 | 10 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 19, 2015 | clinicaltrials |
| NCT01260987 | Fractional CO2 Laser Assisted Photodynamic Therapy | completed | Phase 2 / Phase 3 | 47 | Bispebjerg HospitalOTHER | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00108121 | Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma | completed | Phase 2 | 60 | PeplinINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT01358045 | Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma | completed | Phase 2 | 128 | Maastricht University Medical CenterOTHER | 1 | Jan 13, 2015 | clinicaltrials |
| NCT01543581 | Vismodegib for Treatment of Basal Cell Carcinoma(Erivedge) | completed | Phase 2 | 3 | Abel Torres, MDOTHER | 0 | Sep 26, 2014 | clinicaltrials |
| NCT01201915 | A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma | completed | Phase 2 | 74 | Genentech, Inc.INDUSTRY | 1 | Jun 24, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00023621 | Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome | completed | Phase 2 | 60 | University of California, San FranciscoOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00002963 | Photodynamic Therapy in Treating Patients With Skin Cancer | completed | Phase 2 | — | Roswell Park Cancer InstituteOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00988455 | Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma With 6 Months Follow-up | completed | Phase 1 / Phase 2 | 28 | Shahid Beheshti University of Medical SciencesOTHER | 0 | Oct 2, 2009 | clinicaltrials |
| NCT00586040 | Photochemical Tissue Bonding(PTB) | completed | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Apr 10, 2009 | clinicaltrials |
| NCT00108134 | Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma | completed | Phase 2 | 60 | PeplinINDUSTRY | 1 | Dec 24, 2008 | clinicaltrials |
| NCT00188370 | Ultrasound Biomicroscopy - Apoptosis | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | Sep 16, 2005 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials